

RafaÅ, SuwiÅ,,ski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4260986/publications.pdf>

Version: 2024-02-01

74
papers

1,909
citations

331670

21
h-index

265206

42
g-index

74
all docs

74
docs citations

74
times ranked

2632
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2168-2174.	2.2	5
2	Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2239.	2.4	6
3	Systemic treatment in patients with malignant pleural mesothelioma — real life experience. <i>BMC Cancer</i> , 2022, 22, 432.	2.6	2
4	Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. <i>Cancers</i> , 2022, 14, 2123.	3.7	2
5	Sequential treatment with targeted and immune checkpoint inhibitor therapies in patients with BRAF positive metastatic melanoma: Real-world data.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21539-e21539.	1.6	1
6	Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?. <i>Journal of Clinical Oncology</i> , 2022, 40, e21544-e21544.	1.6	0
7	Tumor regression grading after preoperative hyperfractionated radiotherapy/chemoradiotherapy for locally advanced rectal cancers: interim analysis of phase III clinical study. <i>Neoplasma</i> , 2021, 68, 631-637.	1.6	1
8	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021, 13, 297-307.	2.0	6
9	Prophylactic cranial irradiation in SCLC. <i>Translational Lung Cancer Research</i> , 2021, 10, 2071-2078.	2.8	7
10	Polymorphisms in EGFR Gene Predict Clinical Outcome in Unresectable Non-Small Cell Lung Cancer Treated with Radiotherapy and Platinum-Based Chemoradiotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5605.	4.1	9
11	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 727-736.	10.7	45
12	Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 3315-3322.	1.4	11
13	Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2021, 39, e21514-e21514.	1.6	2
14	NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™, Pan-Cancer Cell-Free Assay. <i>Genes</i> , 2021, 12, 1080.	2.4	4
15	Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. <i>Melanoma Research</i> , 2021, 31, 49-57.	1.2	4
16	A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 4511-4525.	2.8	6
17	Mathematical model predicts response to chemotherapy in advanced non-resectable non-small cell lung cancer patients treated with platinum-based doublet. <i>PLoS Computational Biology</i> , 2020, 16, e1008234.	3.2	12
18	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	1.2	14

#	ARTICLE	IF	CITATIONS
19	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020, 65, 316-323.	2.1	12
20	Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy. <i>Wspolczesna Onkologia</i> , 2020, 24, 34-41.	1.4	4
21	Significance of HPV16 Viral Load Testing in Anal Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 2191-2199.	1.9	7
22	Correlation of immunity-related adverse events with survival and response to anti-PD-1 treatment in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15164-e15164.	1.6	0
23	Randomised clinical trial on 7-days-a-week postoperative radiotherapy vs. concurrent postoperative radio-chemotherapy in locally advanced cancer of the oral cavity/oropharynx. <i>British Journal of Radiology</i> , 2020, 93, 20200288.	2.2	0
24	Towards Personalized Radio-Chemotherapy – Learning from Clinical Data vs. Model Optimization. <i>Lecture Notes in Computer Science</i> , 2020, , 371-379.	1.3	0
25	Long-course preoperative chemoradiation versus 5 – 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. <i>Annals of Oncology</i> , 2019, 30, 1298-1303.	1.2	163
26	Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer. <i>BMC Cancer</i> , 2019, 19, 427.	2.6	21
27	Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 566-571.	0.9	13
28	Detection of circulating HPV16 DNA as a biomarker in the blood of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 632-641.	2.0	19
29	Prediction of lung cancer patients' response to combined chemo-radiotherapy using a personalized hybrid model. <i>Mathematica Applicanda</i> , 2019, 47, .	0.0	1
30	High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. <i>Melanoma Research</i> , 2018, 28, 435-441.	1.2	9
31	Radiobiological rationale for Stereotactic Hypofractionated Radiosurgery (SHRS) Part I. LQED2 or BED formalism. <i>Nowotwory</i> , 2018, 68, 8-14.	0.3	2
32	Radiobiological rationale for stereotactic hypofractionated radiosurgery Part II. Normal tissue tolerance – dose constraints. <i>Nowotwory</i> , 2018, 68, 79-86.	0.3	0
33	Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study. <i>British Journal of Radiology</i> , 2017, 90, 20160731.	2.2	4
34	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1221-1237.	10.7	226
35	Cell-cycle gene expression analysis using real time PCR in locally advanced squamous-cell head and neck cancer. <i>Advances in Medical Sciences</i> , 2016, 61, 293-299.	2.1	3
36	Alpha/beta (α/β) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. <i>British Journal of Radiology</i> , 2016, 89, 20150957.	2.2	12

#	ARTICLE	IF	CITATIONS
37	Randomized clinical trial on 7-days-a-week post-operative radiotherapy vs concurrent post-operative radiochemotherapy in locally advanced cancer of the oral cavity/oropharynx: a report on acute normal tissue reactions. <i>British Journal of Radiology</i> , 2016, 89, 20150805.	2.2	2
38	The VEGFR2, COX2 and MMP2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer. <i>International Journal of Cancer</i> , 2015, 137, 2332-2342.	5.1	22
39	The SIPA1 -313A&G polymorphism is associated with prognosis in inoperable non-small cell lung cancer. <i>Tumor Biology</i> , 2015, 36, 1273-1278.	1.8	7
40	The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer. <i>Radiation Oncology</i> , 2015, 10, 60.	2.7	6
41	Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. <i>British Journal of Cancer</i> , 2015, 112, 1114-1120.	6.4	46
42	Does Routine Clinical Practice Reproduce the Outcome of Large Prospective Trials? The Analysis of Institutional Database on Patients with Limited-Disease Small-Cell Lung Cancer. <i>Cancer Investigation</i> , 2014, 32, 1-7.	1.3	6
43	Early closure of phase II prospective study on acute and late tolerance of hypofractionated radiotherapy in low-risk prostate cancer patients. <i>Reports of Practical Oncology and Radiotherapy</i> , 2014, 19, 337-342.	0.6	6
44	Radiation-Free Weekend Rescued! Continuous Accelerated Irradiation of 7-Days per Week Is Equal to Accelerated Fractionation With Concomitant Boost of 7 Fractions in 5-Days per Week: Report on Phase 3 Clinical Trial in Head-and-Neck Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 741-746.	0.8	11
45	Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: Association with tumor progression. <i>International Journal of Oncology</i> , 2012, 40, 148-56.	3.3	12
46	PTEN as a Prognostic and Predictive Marker in Postoperative Radiotherapy for Squamous Cell Cancer of the Head and Neck. <i>PLoS ONE</i> , 2012, 7, e33396.	2.5	49
47	Impact of educational differences as measure of socioeconomic status on survival for breast cancer patients. <i>Wspolczesna Onkologia</i> , 2012, 4, 345-349.	1.4	3
48	Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy. <i>International Journal of Cancer</i> , 2012, 131, E1100-8.	5.1	31
49	Gene Expression from Bronchoscopy Obtained Tumour Samples as a Predictor of Outcome in Advanced Inoperable Lung Cancer. <i>PLoS ONE</i> , 2012, 7, e41379.	2.5	9
50	Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011, 268, 721-726.	1.6	25
51	Predicting the Effect of Accelerated Fractionation in Postoperative Radiotherapy for Head and Neck Cancer Based on Molecular Marker Profiles: Data From a Randomized Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 438-446.	0.8	19
52	The evaluation of 3DRT and IMRT techniques in postoperative radiotherapy for thyroid medullary carcinoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2008, 13, 126-129.	0.6	1
53	Clinical outcome of three fractionation schedules of preoperative radiotherapy for rectal cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2008, 13, 135-143.	0.6	0
54	Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 155-163.	0.6	31

#	ARTICLE	IF	CITATIONS
55	The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study. <i>Radiotherapy and Oncology</i> , 2007, 82, 132-136.	0.6	44
56	Time Factor in Radiotherapy and Chemotherapy for Limited Disease Small-Cell Lung Cancer. <i>Cancer Investigation</i> , 2007, 25, 163-171.	1.3	2
57	Moderately Low Alpha/Beta Ratio for Rectal Cancer May Best Explain the Outcome of Three Fractionation Schedules of Preoperative Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 793-799.	0.8	38
58	The Prognostic Value of Hemoglobin Concentration in Postoperative Radiotherapy of 835 Patients With Laryngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1018-1023.	0.8	11
59	A pilot study of accelerated preoperative hyperfractionated pelvic irradiation with or without low-dose preoperative prophylactic liver irradiation in patients with locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2006, 80, 27-32.	0.6	11
60	Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: Long-term results of Phase III clinical trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 706-713.	0.8	66
61	Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial. Implication for subsequent local excision. <i>Radiotherapy and Oncology</i> , 2005, 76, 234-240.	0.6	92
62	Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: A report on acute normal tissue reactions. <i>Radiotherapy and Oncology</i> , 2005, 77, 58-64.	0.6	15
63	Continuing Maciejewski's debate on radiotherapy for locally advanced prostate cancer: I have even more dilemmas. <i>Reports of Practical Oncology and Radiotherapy</i> , 2004, 9, 81-88.	0.6	0
64	The erythropoietin-receptor pathway modulates survival of cancer cells. <i>Oncogene</i> , 2004, 23, 8987-8991.	5.9	50
65	Clinical radiobiology of stage T2-T3 bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 60-70.	0.8	54
66	Time factor in postoperative radiotherapy: A multivariate locoregional control analysis in 868 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 399-412.	0.8	166
67	How fast is repopulation of tumor cells during the treatment gap?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 229-236.	0.8	101
68	Estimation for paired binomial data with application to radiation therapy. <i>Statistics in Medicine</i> , 2001, 20, 3375-3390.	1.6	1
69	Tumor Volume and Growth Kinetics in Hypothalamic-Chiasmatic Pediatric Low Grade Gliomas. <i>Pediatric Neurosurgery</i> , 1999, 30, 312-319.	0.7	22
70	The effect of heterogeneity in tumor cell kinetics on radiation dose-response. An exploratory investigation of a plateau effect. <i>Radiotherapy and Oncology</i> , 1999, 50, 57-66.	0.6	17
71	Dose-Response Relationship for Prophylactic Cranial Irradiation in Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 40, 797-806.	0.8	68
72	Rapid growth of microscopic rectal cancer as a determinant of response to preoperative radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 42, 943-951.	0.8	56

#	ARTICLE	IF	CITATIONS
73	Radiation dose response for subclinical metastases. Seminars in Radiation Oncology, 1998, 8, 224-228.	2.2	53
74	Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity. Radiotherapy and Oncology, 1996, 40, 137-145.	0.6	123